Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Hiroshi_Nomura
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:formerName |
gptkb:Dainippon_Sumitomo_Pharma_Co.,_Ltd.
|
| gptkbp:founded |
2005
|
| gptkbp:headquarters_location |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dainippon Sumitomo Pharma
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:JapaneseName |
大日本住友製薬株式会社
|
| gptkbp:mergedInto |
gptkb:Dainippon_Pharmaceutical
gptkb:Sumitomo_Pharmaceuticals |
| gptkbp:notableProduct |
gptkb:Aptiom
gptkb:Latuda gptkb:Lunesta |
| gptkbp:numberOfEmployees |
about 7,000
|
| gptkbp:officialWebsite |
https://www.ds-pharma.com/
|
| gptkbp:parentCompany |
gptkb:Sumitomo_Chemical
|
| gptkbp:products |
pharmaceutical drugs
|
| gptkbp:researchInterest |
infectious diseases
neurology oncology psychiatry |
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4506
|
| gptkbp:subsidiary |
gptkb:Sumitomo_Pharma_America
|
| gptkbp:bfsParent |
gptkb:Sumitomo_Pharma
|
| gptkbp:bfsLayer |
6
|